Axsome TherapeuticsAXSM +1.83%52 PS Ratio is 17.19 as of Jun. 27, 2026, which is 21% above its 10-year median of 14.15. GuruFocus rates AXSM with a GF Score™ of 52/100 and a GF Value™ of $220.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 936 Biotechnology companies, Axsome Therapeutics ranks worse than 63.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Axsome Therapeutics's share price is $241.67.
Axsome Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $14.06. Hence, Axsome Therapeutics's PS Ratio for today is 17.19.
Warning Sign:
Axsome Therapeutics Inc stock PS Ratio (=17.19) is close to 2-year high of 18.15.
The historical rank and industry rank for Axsome Therapeutics's PS Ratio or its related term are showing as below:
AXSM'
s PS Ratio Range Over the Past 10 Years
Min: 9.94 Med: 14.15 Max: 297.04
Current: 17.19
During the past 13 years, Axsome Therapeutics's highest PS Ratio was 297.04. The lowest was 9.94. And the median was 14.15.
AXSM's PS Ratio is ranked worse than 63.14% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs AXSM: 17.19
During the past 13 years, Axsome Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 118.50% per year. The lowest was 118.50% per year. And the median was 118.50% per year.
Back to Basics: PS Ratio
Axsome Therapeutics (NAS:AXSM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Axsome Therapeutics PS Ratio Related Terms
Axsome Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Axsome Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Axsome Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axsome Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Axsome Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Axsome Therapeutics's Share Price of today is $241.67. Axsome Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Axsome Therapeutics (AXSM) has a PS Ratio of 17.19 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Axsome Therapeutics and its competitors. This is 21% above median its historical median of 14.15. Over the past decade, Axsome Therapeutics' PS Ratio has ranged from 9.94 to 297.04. According to the industry distribution chart, Axsome Therapeutics ranks #591 out of 936 companies in the Biotechnology industry, placing it in the top 63.1%.
Is Axsome Therapeutics' PS Ratio too high?
Axsome Therapeutics' current PS Ratio of 17.19 is 21% above median its 10-year median of 14.15. Over the past 10 years, this metric has ranged from a low of 9.94 to a high of 297.04. The Biotechnology industry median PS Ratio is 9.17. Axsome Therapeutics' value of 17.19 is 87.6% above this industry median. Based on the distribution chart, Axsome Therapeutics ranks #591 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Axsome Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Axsome Therapeutics' PS Ratio compare to IONS and EXEL?
According to the Biotechnology industry distribution chart, Axsome Therapeutics ranks #591 out of 936 companies for PS Ratio. This places Axsome Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.17. Axsome Therapeutics' value of 17.19 is 87.6% above this benchmark. Historically, Axsome Therapeutics' own PS Ratio has ranged from 9.94 to 297.04 over the past decade. While the company's 10-year median is 14.15 vs. the industry median of 9.17, Axsome Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axsome Therapeutics's current PS Ratio of 17.19 is 87.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Axsome Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axsome Therapeutics's current PS Ratio is 17.19, which is 21% above median its own 10-year median of 14.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axsome Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Axsome Therapeutics (AXSM) is currently considered Fairly Valued. The stock's GF Value™ is $220.41, compared to a current price of $241.67 — trading 9.6% above its estimated fair value. The current PS Ratio is 17.19, which is 21% above median its 10-year median of 14.15 and 87.6% above the Biotechnology industry median of 9.17. Axsome Therapeutics' overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Axsome Therapeutics (AXSM), the current PS Ratio is 17.19 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axsome Therapeutics (AXSM) Overvalued in 2026?
Based on GuruFocus' analysis, Axsome Therapeutics stock appears to be overvalued.
The current stock price of $241.67 is trading 9.6% above its estimated GF Value™ of $220.41.
GuruFocus considers Axsome Therapeutics to be Fairly Valued.
Key valuation signals for AXSM:
PS Ratio: 17.19 (21% above median its 10-year median of 14.15)
GF Value™: $220.41 vs. price of $241.67 (9.6% above fair value)
Industry Position: 87.6% above the Biotechnology median (#591 of 936)
No single metric tells the full story. See the AXSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
52GF Score
Get the complete analysis for AXSM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXSM has been successfully added to your 
